Renal & Urology News includes a CME article in every print issue, which will also be available online.
Once you have read the CME article, click on the link at the beginning of each article to take the post-test. To view the full RUN myCME page, click here.
Treatment of LUTS secondary to BPH has evolved from surgical therapy to medical monotherapy, and now combination therapy.
Given the frequency with which these lesions are found, urologists and nephrologists should be familiar with their evaluation.
Emerging data suggest that thyroid hormone deficiency may be associated with greater cardiovascular morbidity and mortality in this population.
Urologists typically treat a renal cortical mass without biopsy, but this should be re-evaluated in the era of the incidental small renal cortical neoplasm.
Scientific speculation suggests that uremic toxins, viral mediators, and immune inhibition could play a role in malignant transformation.
It is hoped that selective screening, selective biopsy, and selective therapy will further decrease the morbidity associated with screening.
The routine incorporation of NMIBC clinical practice guidelines will reduce variation in care by closing the gap on inappropriate delivery, whether over- or underuse.
With increased incidence of obesity—and higher caloric and salt intake—in the general population, resistant hypertension is more prevalent than ever.
Given the intimate anatomical and physiological relationship of the adrenals to the kidney, an understanding of adrenal disease is imperative for urologists and nephrologists alike.
The management of patients with high-risk prostate cancer represents one of the biggest challenges today, with little consensus on optimal treatment.
Clinicians need to keep abreast of the most current treatment options for NGB, which can result in improved patient outcomes and quality of life.
Approximately 30%-50% of SLE patients have clinically evident renal disease at presentation, but renal involvement occurs in up to 60% of patients overall.
A case study involving a 58-year-old man with acute gout attacks and multiple comorbidities, including hypertension and hypercholesterolemia.
Pre-existing renal osteodystrophy at the time of transplantation, reduced renal function, and transplantation-specific therapies are the main contributing factors.
Diagnostics and treatment options for NGB are continually advancing, and clinicians need to remain up-to-date to accurately assess and optimally manage patients